9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      A Scotland Based Cost-Effectiveness Analysis Of Idelalisib (Zydelig®) In Combination With Rituximab For The Treatment Of Adults With Chronic Lymphocytic Leukaemia Cll)

      , , , ,
      Value in Health
      Elsevier BV

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          Value in Health
          Value in Health
          Elsevier BV
          10983015
          November 2015
          November 2015
          : 18
          : 7
          : A455
          Article
          10.1016/j.jval.2015.09.1160
          d2755768-bc1c-44ee-a9dc-1e6484c3408b
          © 2015

          https://www.elsevier.com/tdm/userlicense/1.0/

          https://www.elsevier.com/open-access/userlicense/1.0/

          History

          Comments

          Comment on this article

          Related Documents Log